- Email: [email protected]
S273 Trends in the incidence of germ cell testicular tumors (GCTTs) between 1976 and 2005
S273
Trends in the incidence of germ cell testicular tumors (GCTTs) between 1976 and 2005 Eur Urol Suppl 2013;12;e1381
Argirovic D.1, Argirovic A.2 1Clinic
of Urology, Ccs, Outpatient Clinic Argirovic,, Dept. of Urology, Belgrade, Serbia, 2CHC Zemun, Dept. of Urology, Zemun,
Serbia INTRODUCTION & OBJECTIVES: To prospectively investigate the presentation of GCTTs in terms of clinical stage (CS) or histology, as the incidence of this disease (ds) is increasing. MATERIAL & METHODS: Information was collected from a prospective database initiated in 1966. Patients (pts) diagnosed with GCTTs between 1976 and 2005 were categorized into 3 periods depending on date of diagnosis of the GCTTs and presentation characteristics assessed. For purpose of analysis, pts were assigned to 1 of 3 similar groups in term of duration (10 years [y]) (1976-1985, 1986-1995, 1996-2005). These 3 periods were compared statistically to identify possible changes in the presentation of GCTTs. RESULTS: Among 1935 pts, the number diagnosed in each period was 111 (6%), 695 (36%) and 1129 (58%), respectively. There was substantial arise in the percentage of pts with GCTTs during the period of 30 y, particularly in 3rd vs. 2nd and 1st decade (P<0.0001). The median (range) age of the whole cohort was 34 (14-80) y. The median age for developing metastatic seminoma (S) was 4 y more then in CS I ds (38 vs. 42 y. respectively), while the median age for the presentation of CS I and metastatic nonseminoma (NS) was identical (31 y). Overall, 46% of pts were diagnosed with S and 54% with NS. The proportion of S increased significantly in time (48% vs. 55%), and this was accompanied by a significant decrease in NS (60% vs. 45%) (P<0.001). The proportion of pts with CS I ds also increased significantly with time (45% vs. 77%), while the proportion of pts with metastatic ds decreased (55% vs. 29%) (P<0.001). In the most recent period 77% had CS I and 23% had metastatic ds. There was a significant rise in proportion of pts with CS I S (27% vs. 47%) and NS (18% vs. 30%), accompanied by a significant decrease in the proportion of pts presenting with metastatic NS (42% vs. 15%)(P<0.001). However, the proportion of patients with metastatic S remained largely unchanged (13% vs. 9%). CONCLUSIONS: The present study chows an increase in the proportion of pts with GCTTs in CS I. This is good news for pts with GCTTs, as it not only reduces the need for chemotherapy and/or cytoreductive surgery, but also is associated with better long-term survival. The other finding is that there has been an increase in the proportion of pts presenting with S rather than NS. The reasons for these remains unclear and require further investigation.
Trends in the incidence of germ cell testicular tumors (GCTTs) between 1976 and 2005 Eur Urol Suppl 2013;12;e1381
Argirovic D.1, Argirovic A.2 1Clinic
of Urology, Ccs, Outpatient Clinic Argirovic,, Dept. of Urology, Belgrade, Serbia, 2CHC Zemun, Dept. of Urology, Zemun,
Serbia INTRODUCTION & OBJECTIVES: To prospectively investigate the presentation of GCTTs in terms of clinical stage (CS) or histology, as the incidence of this disease (ds) is increasing. MATERIAL & METHODS: Information was collected from a prospective database initiated in 1966. Patients (pts) diagnosed with GCTTs between 1976 and 2005 were categorized into 3 periods depending on date of diagnosis of the GCTTs and presentation characteristics assessed. For purpose of analysis, pts were assigned to 1 of 3 similar groups in term of duration (10 years [y]) (1976-1985, 1986-1995, 1996-2005). These 3 periods were compared statistically to identify possible changes in the presentation of GCTTs. RESULTS: Among 1935 pts, the number diagnosed in each period was 111 (6%), 695 (36%) and 1129 (58%), respectively. There was substantial arise in the percentage of pts with GCTTs during the period of 30 y, particularly in 3rd vs. 2nd and 1st decade (P<0.0001). The median (range) age of the whole cohort was 34 (14-80) y. The median age for developing metastatic seminoma (S) was 4 y more then in CS I ds (38 vs. 42 y. respectively), while the median age for the presentation of CS I and metastatic nonseminoma (NS) was identical (31 y). Overall, 46% of pts were diagnosed with S and 54% with NS. The proportion of S increased significantly in time (48% vs. 55%), and this was accompanied by a significant decrease in NS (60% vs. 45%) (P<0.001). The proportion of pts with CS I ds also increased significantly with time (45% vs. 77%), while the proportion of pts with metastatic ds decreased (55% vs. 29%) (P<0.001). In the most recent period 77% had CS I and 23% had metastatic ds. There was a significant rise in proportion of pts with CS I S (27% vs. 47%) and NS (18% vs. 30%), accompanied by a significant decrease in the proportion of pts presenting with metastatic NS (42% vs. 15%)(P<0.001). However, the proportion of patients with metastatic S remained largely unchanged (13% vs. 9%). CONCLUSIONS: The present study chows an increase in the proportion of pts with GCTTs in CS I. This is good news for pts with GCTTs, as it not only reduces the need for chemotherapy and/or cytoreductive surgery, but also is associated with better long-term survival. The other finding is that there has been an increase in the proportion of pts presenting with S rather than NS. The reasons for these remains unclear and require further investigation.